<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>470</serviceExecutionTime><Drug id="93114"><DrugName>BMS-986142</DrugName><DrugSynonyms><Name><Value>BMS-986142</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesPrimary><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesPrimary><CrossReferences><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="1148" type="ciIndication"><TargetEntity id="M35.0" type="ICD10"></TargetEntity><TargetEntity id="710.2" type="ICD9"></TargetEntity><TargetEntity id="10040767" type="MEDDRA"></TargetEntity><TargetEntity id="D012859" type="MeSH"></TargetEntity><TargetEntity id="-459977592" type="omicsDisease"></TargetEntity><TargetEntity id="734" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="3592" type="Action"><TargetEntity id="1668" type="Mechanism">Bruton's Tyrosine Kinase (BTK) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00229" type="ciTarget"><TargetEntity id="6158038666953" type="siTarget">Tyrosine-protein kinase BTK</TargetEntity><TargetEntity id="93" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><IndicationsPrimary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1148">Sjoegrens syndrome</Indication></IndicationsSecondary><ActionsPrimary><Action id="3592">Btk tyrosine kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-03-25T03:06:45.000Z</LastModificationDate><ChangeDateLast>2019-02-11T00:00:00.000Z</ChangeDateLast><AddedDate>2014-10-10T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) is developing the Bruton tyrosine kinase (Btk) inhibitor BMS-986142 for the potential oral treatment of rheumatoid arthritis (RA) [&lt;ulink linkID="1601204" linkType="Reference"&gt;1601204&lt;/ulink&gt;], [&lt;ulink linkID="1742654" linkType="Reference"&gt;1742654&lt;/ulink&gt;], [&lt;ulink linkID="1784688" linkType="Reference"&gt;1784688&lt;/ulink&gt;], [&lt;ulink linkID="1793650" linkType="Reference"&gt;1793650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In February 2016, a phase II RA study was initiated. In May 2018, the trial was completed   [&lt;ulink linkID="1724596" linkType="Reference"&gt;1724596&lt;/ulink&gt;]. In January 2019, the drug was listed on BMS' pipeline as being in phase II [&lt;ulink linkID="2117890" linkType="Reference"&gt;2117890&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Bristol-Myers Squibb was previously developing the drug for the potential treatment of  Sjogren's syndrome [&lt;ulink linkID="1601204" linkType="Reference"&gt;1601204&lt;/ulink&gt;], [&lt;ulink linkID="1742654" linkType="Reference"&gt;1742654&lt;/ulink&gt;], [&lt;ulink linkID="1784688" linkType="Reference"&gt;1784688&lt;/ulink&gt;], [&lt;ulink linkID="1793650" linkType="Reference"&gt;1793650&lt;/ulink&gt;]. In October 2016, a phase II trial began in Sjogren's syndrome.  In June 2017, the trial was terminated due to failure to meet protocol objectives and its is presumed that development for the indication was discontinued [&lt;ulink linkID="1784688" linkType="Reference"&gt;1784688&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;subtitle&gt;Sjogren's syndrome&lt;/subtitle&gt;In October 2016, a randomized, multicenter, double-blind, placebo-controlled phase II study (&lt;ulink linkID="266454" linkType="Protocol"&gt;NCT02843659&lt;/ulink&gt;; IM128-035) began in patients (expected n = 120) with moderate to severe primary Sjogren's syndrome to assess the safety and efficacy of &lt;ulink linkID="90075" linkType="Drug"&gt;BMS-931699&lt;/ulink&gt; (lulizumab) or BMS-986142 in the  US, Chile,  Italy, Mexico, Peru and Puerto Rico. The trial was also planned to begin in Australia, Colombia, France, Hungary, Poland, Russia and South Africa. The primary endpoint was change from baseline in ESSDAI score at week 12. In April 2017, completion of the study was expected in September 2018. In June 2017, the trial was terminated due to the inability to meet protocol objectives  [&lt;ulink linkID="1784688" linkType="Reference"&gt;1784688&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;In February 2016, a randomized, double-blind, parallel assigned, safety/efficacy, placebo-controlled, dose-ranging, multicenter, phase II study (&lt;ulink linkID="249368" linkType="Protocol"&gt;NCT02638948&lt;/ulink&gt;; IM006-016, 2015-002887-17) was initiated in  patients (expected n = 408) with moderate to severe rheumatoid arthritis. At that time, the study was expected to complete in July 2019 [&lt;ulink linkID="1724596" linkType="Reference"&gt;1724596&lt;/ulink&gt;].  In July 2016, the trial was initiated in Taiwan [&lt;ulink linkID="1787340" linkType="Reference"&gt;1787340&lt;/ulink&gt;]. In August 2016, the trial was also ongoing in Canada, Japan, Mexico and Spain. At that time, the trial was planned in Argentina, Europe, Brazil, and South Korea [&lt;ulink linkID="1724596" linkType="Reference"&gt;1724596&lt;/ulink&gt;]. By November 2016, the trial was also recruiting in Russia and South Africa. In May 2018, the trial was completed [&lt;ulink linkID="1724596" linkType="Reference"&gt;1724596&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In August 2016,  an open-label, single-dose, phase I study (&lt;ulink linkID="269855" linkType="Protocol"&gt;NCT02880670&lt;/ulink&gt;; IM006-022) to assess the pharmacokinetics, metabolism and routes of elimination of a single oral dose of radiolabeled BMS-986142 in healthy male subjects (expected n = 9), was initiated in the US. The study was to complete in September 2016 [&lt;ulink linkID="1793650" linkType="Reference"&gt;1793650&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, an open-label, non-randomized, interventional,  parallel asssignment,  2-cycle, multiple-dose, single-sequence phase I trial (&lt;ulink linkID="265754" linkType="Protocol"&gt;NCT02832180&lt;/ulink&gt;; IM006-032) was initiated in the US in patients (expected n = 24) with arthritis to assess the effect of BMS-986142 on the pharmacokinetics (PK) of combined oral contraceptive containing ethinyl estradiol and norethindrone acetate. At that time, the trial was expected to complete in August 2016      [&lt;ulink linkID="1780993" linkType="Reference"&gt;1780993&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase I study (&lt;ulink linkID="212467" linkType="Protocol"&gt;NCT02257151&lt;/ulink&gt;; IM006-001) was initiated  in the US in healthy subjects (n = 40). The trial was expected to complete in August 2015 [&lt;ulink linkID="1601204" linkType="Reference"&gt;1601204&lt;/ulink&gt;]. In March 2016, data from the trial were presented at the 117th ASCPT Annual Meeting in San Diego, CA. The Cmax values after single doses of the drug (4 to 900 mg) ranged from 9.032 to  1878.430 ng/ml; the median Tmax values ranged from 1.00 to 2.03 h; and the AUCinf range d from 101.960 to 28062.751 ng*h/ml. After multiple ascending doses of the drug (25, to  350 mg, qd, 14 days), the  Cmax values were  from 55.957 to 1024.177 ng/ml, Tmax values were from 1.50 to 2 h, and the AUCTau were from 538.834, to 10,715.371 ng*h/ml. Results from a QT interval study indicated no significant cardiovascular risks across the dose range studied [&lt;ulink linkID="1742654" linkType="Reference"&gt;1742654&lt;/ulink&gt;], [&lt;ulink linkID="1742662" linkType="Reference"&gt;1742662&lt;/ulink&gt;]. In June 2016, further results were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. In MAD study, geometric mean Cmax (ng/ml), median Tmax (h), geometric mean Cmin (ng/ml), geometric mean AUC(tau) (ngxh/ml), geometric mean accumulation index (ratio) and mean t1/2 (h) values were 56.0, 2.00, 7.85, 539, 1.57 and 10.0 for BMS-986142 at 25 mg; 281, 2.00, 27.9, 2471, 1.23 and 10.7 for BMS-986142 at 75 mg; 592, 2.00, 67.6, 5527, 1.23 and 11.0 for BMS-986142 at 200 mg and 1024, 1.50, 166, 10,715, 0.98 and 10.2 for BMS-986142 at 350 mg, respectively. In the SAD study, estimated slope values for Cmax (ng/ml), AUC(0 to last quantifiable time) (hxng/ml) and AUC(0 to infinite time) (ngxh/ml) were 1.050, 1.125 and 1.089, respectively. BMS-986142 did not impact the maximum observed concentration and AUC(0 to infinite time) of methotrexate [&lt;ulink linkID="1767879" linkType="Reference"&gt;1767879&lt;/ulink&gt;].  In April 2017, further data were presented at the 253rd ACS National Meeting and Exhibition in San Francisco, CA. Single and multiple ascending doses of BMS-986142 (5 to 900 mg and 25 to 350 mg, respectively) were well tolerated [&lt;ulink linkID="1914671" linkType="Reference"&gt;1914671&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2018, preclinical data were presented at the 255th ACS National Meeting and Exposition in New Orleans, LA. In a collagen antibody-induced arthritis mouse model, clear dose response was observed and BMS-986142 was effective at 5 and 20 mg/kg (po, qd). It was observed that an approximately 16 h coverage of mouse WB IC50 of 140 nM was needed for robust efficacy. In a mouse model of collagen-induced arthritis, BMS-986142 at doses 15 and 30 mg/kg (po, qd) produced a &amp;gt; 70% decrease in clinical scores [&lt;ulink linkID="2013459" linkType="Reference"&gt;2013459&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 253rd ACS National Meeting and Exhibition in San Francisco, CA. In a mouse model of RA, BMS-986142 (5 and 20 mg/kg, po, qd) showed a dose-response efficacy [&lt;ulink linkID="1914671" linkType="Reference"&gt;1914671&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-07-29T00:00:00.000Z</StatusDate><Source id="1787340" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-02-17T00:00:00.000Z</StatusDate><Source id="1724596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PE">Peru</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-14T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1601204" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-07-08T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PE">Peru</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CO">Colombia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1148">Sjoegrens syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-10-26T00:00:00.000Z</StatusDate><Source id="1784688" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00229"><Name>Btk tyrosine kinase</Name><SwissprotNumbers><Swissprot>P35991</Swissprot><Swissprot>Q06187</Swissprot><Swissprot>Q8JH64</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2117890" linkType="reference" linkID="2117890"&gt;2117890&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cc1c(cccc1n2c(=O)c3cccc(c3n(c2=O)C)F)c4c(cc(c5c4c6c([nH]5)C[C@H](CC6)C(C)(C)O)C(=O)N)F</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2852207" number="WO-2014210085" title="Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors"></PatentFamily><PatentFamily id="4105309" number="WO-2018118830" title="Process for preparing tetrahydrocarbazole carboxamide compound"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>